



NEUWAY
P H A R M A

NEUWAY Pharma GmbH appoints Dr. Stephan Rapp as CEO

Bonn, July 16, 2014. NEUWAY Pharma GmbH, a biotech start-up company focusing on the development of innovative drugs on the basis of its proprietary CNS delivery technology, today announced that it has appointed Dr. Stephan Rapp as Chief Executive Officer and Managing Director. NEUWAY Pharma GmbH was founded in April 2014 as the first spin-off from Life Science Inkubator GmbH, Bonn, and received its series A financing from a syndicate led by Wellington Partners.

For the last 12 months Dr. Stephan Rapp has been advising start-up companies in the field of biotechnology and medical devices in his role as Founder and Managing Director at bioenco consulting GmbH. Prior to this, Dr. Rapp was a Member of the Executive Board of Tetec AG, a tissue engineering company majority-owned by the B.Braun Group, with responsibility for finance, sales & marketing as well as human resources. His previous positions included Senior Investment Manager at venture capital investor SHS, Managing Director at the Bavarian Red Cross overseeing their blood donation, stem cell transplant and tissue engineering activities, and various senior positions in clinical development at Wyeth/Genetics Institute, Pharmed Labs and Fujisawa. Dr. Rapp obtained his Ph.D. with distinction (“summa cum laude”) from University of Heidelberg and holds a MSc in Biology and a Diploma as Financial Analyst from DVFA.

Dr. Heiko Manninga, Co-Founder, CSO and Managing Director at NEUWAY, commented: “We are very happy to strengthen our company with the addition of Dr. Stephan Rapp as CEO who has been introduced to us by our lead investor Wellington Partners. He has a lot of experience from managing small and medium-sized enterprises, from preclinical and clinical development through production, sales and marketing as well as finance, and therefore has exactly the right background to take this company to the next level. I am very much looking forward to working with him.”

Dr. Rainer Strohmenger, Chairman at NEUWAY and General Partner at Wellington Partners, added: “Experience tells us that management is making the difference in any of our companies. I have been following Dr. Stephan Rapp’s career for a long time. He has been successful in whatever he has been doing so far, and I have no doubt that he will significantly contribute to developing the full value of NEUWAY’s unique technology to deliver drugs to the CNS.”

Further information:

Dr. Rainer Strohmenger

Chairman NEUWAY Pharma GmbH

Tel: +49 89 21994116

Mail: strohmenger@wellington-partners.com



NEUWAY
P H A R M A

About NEUWAY Pharma

NEUWAY Pharma GmbH, Bonn, Germany, is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases based on its proprietary CNS drug delivery platform. The company also intends to partner its drug delivery technology for other CNS indications.

NEUWAY had been founded in April 2014 as the first spin-off from Life Science Inkubator GmbH, Bonn, Germany, where it had been incubated for the last 4 years and supported with approx. € 2.3 million in research funding by the Federal Ministry of Education and Research. The company closed a series A financing round in May 2014 with a volume of € 2.7 million provided by a syndicate led by Wellington Partners.